Stockreport

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

Organogenesis Holdings Inc. - Class A  (ORGO) 
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm Check Earnings Report
PDF Statistically significant (p=0.0177) reduction in knee pain at six monthsStatistically significant (pTransformational opportunity for Organogenesis to enter large and gr [Read more]